Join our smart investors - Get the best stock directories in  blockchain, cannabis, crypto, AI, IoT, cleantech. Daily podcasts in cannabis and crpto. Just $99  a year

United States Medical #Marijuana Market Forecast 2018-2022: Medical Cannabis Revenue will Overtake Recreational in the Next 4 Years


DUBLIN - August 9, 2018 ( Newswire) The "US Medical Marijuana Market, Forecast to 2022" report has been added to's offering.

The medical marijuana market is growing in the United States despite the fact that the Food and Drug Administration (FDA) has not yet approved any medical marijuana products. These marijuana-based products have not yet passed through the rigorous tests and clinical trials required for medical drug approvals in the United States. At the Federal level, marijuana is still considered an illegal Schedule 1 drug. Individual states, however, have laws in place for the legal use of medical marijuana, and in some states, for the use of recreational marijuana. Cannabidiol (CBD) products are also legally available in some US states as well as in many other countries. The market generates a lot of money, though much of that money is still considered a black market.

Many business segments are involved with the development of the medical marijuana market. Some businesses directly touch the plant product, such as growers, packers, transporters, and sellers. Other businesses operate in the medical marijuana industry but do not touch the plant product, including legal services, marketing and brand services, data and analytical services, insurance participants and hardware or software companies. The rules differ depending upon where a company stands related to the marijuana plant. This is a very different model than is in place for traditional pharmaceutical products.

The medical marijuana segment of the marijuana industry includes marijuana plant products, CBD products, and synthetically derived products targeting the cannabidiol receptors CB1 and CB2. There are several synthetic products currently on the markets in many countries other than the US. As a matter of fact, in Canada, not only is medical marijuana approved for use on the national level, its use is covered by Health Canada, the national government insurance plan.

In the US, medical marijuana use is increasing, as many more states have approved it for use in several diseases. In addition, hundreds of clinical trials are underway, testing products under the watchful eye of the FDA. It has been reported in states where medical marijuana is approved for use for the treatment of pain, there have reductions in the use of opioid drugs. This decrease in opioid use may prove to be a valuable mechanism to curb the current opioid epidemic in the US.

Legal uncertainty related to the use of medical marijuana has limited big pharma investments into this space; however in non-US locations, companies are more interested in pursuing this area of research and development. Billions of dollars are being generated through this market. It is a growing market drawing keen interest from physicians, investors and regulators. Physician education will be crucial, as these products gain approval, as cannabis was not a part of the medical curriculum of many currently practicing physicians.

Key Topics Covered:


  • Key Findings
  • Scope and Segmentation
  • Key Questions this Study will Answer
  • Cannabis Segment Overview
  • CBD Segment Overview
  • Marijuana Market - Definitions and Market Segments
  • Market Engineering Measurements
  • Companies to Watch
  • 3 Big Predictions


  • Cannabis Primer
  • Cannabinoids
  • Endocannabinoid System
  • Hemp Derived CBD Market
  • Federal Laws Regarding Cannabis & CBD Regulation
  • Federal Laws Regarding Hemp Regulation
  • Federal Oversight in Medical Cannabis Industry
  • Medical Cannabis - Federal versus State Regulations*
  • State-Specific Approved Marijuana/CBD Use
  • Medical Marijuana Business Sector Landscape
  • Medical Cannabis
  • Medical Cannabis Impact on Opioid Use
  • Cannabidiol (CBD)
  • CBD Impact on Healthcare Treatments
  • Cannabinoid (CB1 & CB2) Drugs in Development
  • 2018 Marijuana Conferences


  • FDA-Approved Cannabinoid-Based Synthetic Products
  • Market Opportunities
  • Disruptive Market Participants
  • Funding Assessment
  • Private Company Equity Deals


  • Market Drivers
  • Drivers Explained
  • Market Restraints
  • Restraints Explained


  • Forecast Assumptions and Definitions
  • Methodology and Forecast Assumptions
  • Medical Marijuana Market - An Overview
  • Medical Cannabis Revenue by State
  • Medical Marijuana Forecast by Segment
  • Revenue Forecast Discussion


  • Key Findings for Medical Cannabis
  • Transformation in the Medical Marijuana Industry Ecosystem, 2018
  • Medical Cannabis - Regional Picture
  • Medical Cannabis - Patients by State
  • Market Engineering Metrics
  • Medical Cannabis Revenue Forecast
  • Revenue Forecast Discussion
  • Revenue Forecast by Sub-segment
  • Revenue Forecast by Sub-segment Discussion


  • Key Findings for CBD
  • Market Engineering Metrics
  • CBD Revenue Forecast to 2022
  • Revenue Forecast Discussion
  • CBD Sub-segment Revenue Forecast
  • Revenue Forecast by Sub-segment Discussion


  • The Last Word - 3 Big Predictions
  • Legal Disclaimer


For more information about this report visit

Laura Wood, Senior Manager

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Related Topics: Analgesics

Marijuana / Hemp Stocks

Marijuana / Hemp Stocks

Like Marijuana / Hemp Stocks? View our Marijuana / Hemp Stocks Directory

Join our Group on Linkedin - Marijuana / Hemp Stocks - News and Trends in Green Investing

Global Cannabis Investing - features Investor Ideas Cannabis news

Get News Alerts on Marijuana Stocks

More Info: Newswire

This news is published on the Newswire - a global digital news source for investors and business leaders

Disclaimer/Disclosure: is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: Learn more about publishing your news release on the newswire

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: Global investors must adhere to regulations of each country.

Please read privacy policy: